

References

I-274

1. Columvi™ (glofitamab-gxbm) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised 06/2023.
2. Clinical Pharmacology™ 2023. Tampa FL: Gold Standard, Inc. Glofitamab.
3. Micromedex DrugDex Compendium®. 2023. Glofitamab-gxbm.
4. National Comprehensive Cancer Network (NCCN). Glofitamab-gxbm. NCCN Drugs and Biologics Compendium®. 2023.
5. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2022;387(24):2220-2231.
6. Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting t-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: A Phase I trial. *J Clin Oncol*. 2021;39(18):1959-1970.